Abstract
This review examines the differences in the incidence, spectrum, and mechanisms of activation of opportunistic infections, such as Mycobacterium tuberculosis, in patients with rheumatic diseases treated with the soluble TNF p75 receptor etanercept compared to the 2 anti-TNF-alpha monoclonal antibodies, infliximab and adalimumab.